Trial reportPediatrics2019
Treating Hypertension in Children With
Trial report in Pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Narrative update of clinical trials with antihypertensive drugs in children and adolescents.Frontiers in cardiovascular medicine · 2022Pooled it
- Comparison of Bayesian Networks, G-estimation and linear models to estimate causal treatment effects in aggregated N-of-1 trials with carry-over effects.BMC medical research methodology · 2023Trial
- Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.JAMA · 2023Trial
- N-of-1 Trials vs. Usual Care in Children With Hypertension: A Pilot Randomized Clinical Trial.American journal of hypertension · 2023Trial
- Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.Nature medicine · 2023Trial
- Precision approaches to paediatric hypertension: linking pathophysiology to therapy.Pediatric nephrology (Berlin, Germany) · 2026Review
- Blueprint for clinical N-of-1 strategies with off-label precision treatments in monogenic epilepsies.Orphanet journal of rare diseases · 2025Review
- Pediatric Blood Pressure and Cardiovascular Health in Adulthood.Current hypertension reports · 2024Review
- The development of a set of key points to aid clinicians and researchers in designing and conducting n-of-1 trials.Trials · 2024Article
- Treatment of Hypertension in Children.Current hypertension reviews · 2024Review
- N-of-1 Trials for Pediatric Hypertension? A Promising Approach to Increasing the Precision of Antihypertensive Treatment.American journal of hypertension · 2023Article
- Physician-Pharmacist Collaborative Drug Therapy Management in Pediatric Hypertension.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study.Frontiers in pediatrics · 2023Article
- High Blood Pressure in Children and Adolescents: Current Perspectives and Strategies to Improve Future Kidney and Cardiovascular Health.Kidney international reports · 2022Review
- Evaluating Personalized (N-of-1) Trials in Rare Diseases: How Much Experimentation Is Enough?Harvard data science review · 2022Article
- Personalized Trial Ethics and Institutional Review Board Submissions.Harvard data science review · 2022Article
- Blood Pressure in Childhood and Adolescence.American journal of hypertension · 2021Review
- Personal preferences for Personalised Trials among patients with chronic diseases: an empirical Bayesian analysis of a conjoint survey.BMJ open · 2020Article
- Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.PloS one · 2020Article
- Comparison of Aggregated N-of-1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies.Healthcare (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesClinicians prescribe antihypertensive medication to children with primary hypertension, but without data to define a particular choice as first-line therapy. A one-size-fits-all approach may not be appropriate for these patients. Our aim was to develop a personalized approach to hypertension treatment, using repeated ambulatory blood pressure monitoring (ABPM) in
methodsChildren undergoing hypertension management at a single pediatric referral center were offered participation in an
resultsForty-two children agreed to participate; 7 were normotensive without medication; and 3 failed to complete one treatment cycle. Of the remaining 32 patients, lisinopril was preferred for 16, amlodipine for 8, hydrochlorothiazide for 4, and 4 had uncontrolled blood pressure on maximum doses of monotherapy. In conservative Bayesian analyses, the proportion of patients who preferred lisinopril was 49% (95% credible interval [CrI]: 32% to 69%), 24% (95% CrI: 12% to 41%) preferred amlodipine, and 12% (95% CrI: 4% to 26%) preferred hydrochlorothiazide. The preferred therapy for the majority (67%) of African American participants was lisinopril. Unacceptable side effects were reported in 24% of assessments for hydrochlorothiazide, 16% for lisinopril, and 13% for amlodipine.
conclusionsNo single medication was preferred for more than half of hypertensive children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.